TY - JOUR
KW - Administration, Inhalation
KW - Adrenal Cortex Hormones/therapeutic use
KW - Adrenergic beta-2 Receptor Agonists/adverse effects
KW - Adult
KW - Bronchodilator Agents/adverse effects
KW - Cohort Studies
KW - Drug Therapy, Combination
KW - Formoterol Fumarate/adverse effects
KW - Humans
KW - Muscarinic Antagonists/adverse effects
KW - *Myocardial Infarction/chemically induced/diagnosis/epidemiology
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
KW - Risk Assessment
KW - *Stroke/diagnosis/epidemiology
KW - Tiotropium Bromide/adverse effects
KW - Lama
KW - United Kingdom
KW - aclidinium
KW - Acute myocardial infarction
KW - Stroke
AU - C. Rebordosa
AU - E. Plana
AU - A. Rubino
AU - J. Aguado
AU - D. Martinez
AU - A. Lei
AU - S. Daoud
AU - N. Saigi-Morgui
AU - S. Perez-Gutthann
AU - E. Rivero-Ferrer
AD - Department of Epidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
Department of Biometrics, RTI Health Solutions, Barcelona, Spain.
Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK.
Patient Safety Biopharma, AstraZeneca, Barcelona, Spain.
BioPharmaceuticals Research and Development, Late-Stage Development Respiratory and Immunology, AstraZeneca, Gaithersburg, MD, USA.
AN - 35941901
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC9356604
DO - 10.2147/copd.s363997
DP - NLM
ET - 2022/08/10
LA - eng
N1 - 1178-2005
Rebordosa, Cristina
Orcid: 0000-0002-8064-5997
Plana, Estel
Orcid: 0000-0001-8675-7503
Rubino, Annalisa
Aguado, Jaume
Orcid: 0000-0002-9575-0212
Martinez, David
Orcid: 0000-0001-7001-7674
Lei, Alejhandra
Daoud, Sami
Saigi-Morgui, Nuria
Orcid: 0000-0003-2503-1818
Perez-Gutthann, Susana
Orcid: 0000-0001-5798-3691
Rivero-Ferrer, Elena
Orcid: 0000-0001-5093-2445
Journal Article
Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-1733. doi: 10.2147/COPD.S363997. eCollection 2022.
PY - 2022
SN - 1176-9106 (Print)1176-9106
SP - 1715
EP - 1733
T2 - Int J Chron Obstruct Pulmon Dis
TI - Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
VL - 17
ER -